More Aggressive Therapy Needed for Many Patients With Familial Hypercholesterolemia
Even with care in specialty clinics, LDL-C persists above target levels in more than half of patients with familial hypercholesterolemia.
Familial Hypercholesterolemia
Studies Show Inclisiran Benefits Patients With HeFH, ASCVD, and Elevated LDL-C
Full detailed data will be presented at the AHA Scientific Sessions in Philadelphia in November 2019.
Lomitapide Reduces LDL-C Levels in Homozygous Familial Hypercholesterolemia
Lomitapide reduced low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia, with some patients reaching recommended targets.
Evinacumab Effective in Homozygous Familial Hypercholesterolemia Trial
Results from a phase 3 trial evaluating the efficacy of evinacumab (Regeneron) in the treatment of patients with homozygous familial hypercholesterolemia (HoFH) showed that the investigational angiopoietin-like 3 (ANGPTL3) antibody reduced low-density lipoprotein (LDL) cholesterol by 49%.
Monogenic Familial Hypercholesterolemia Increases Premature CVD Risk
Investigators sought to determine whether a monogenic cause substantially increases the risk for premature cardiovascular disease in patients with familial hypercholesterolemia.
RNAi Therapy for Homozygous Familial Hypercholesterolemia Receives Orphan Drug Designation
ARO-ANG3 reduces production of ANGPTL3, which has been shown to lower serum LDL as well as serum and liver triglyceride.
FDA Approves Sprinkle Formulation of Rosuvastatin
Ezallor Sprinkle is intended for patients who have difficulty swallowing.
Livalo Approved for Pediatric Patients With Heterozygous Familial Hypercholesterolemia
Livalo is indicated for pediatric patients ≥8 years old with HeFH to reduce TC, LDL-C, and Apo-B.
LDL and DLCNC Score May Identify Familial Hypercholesterolemia
A low-density lipoprotein-cholesterol level >4.9 mmol/L in addition to the Dutch Lipid Clinic Network Criteria score may help identify probable/definite or possible familial hypercholesterolemia.
Blood Donor Screening Data May Identify Familial Hypercholesterolemia
Data from a blood donor screening program could represent a novel strategy for identifying familial hypercholesterolemia.
Next post in News
